Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
(4) - EconoTimes)
SOUTH SAN FRANCISCO, Calif., May 10, 2017 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that the compensation committee of Atara’s board of directors, approved a grant, effective as of May 10, 2017, to Dr. Derrell Porter in connection with his employment at the Company, of a non-qualified stock option to purchase 130,000 shares of Atara’s common stock. This option was granted as an inducement material to the employee's entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
The stock option has a seven-year term and an exercise price of $14.30, equal to the per share closing price of Atara’s common stock as reported by NASDAQ on the date of grant. The stock option will vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting over the following three years, assuming the employee is continuously employed by Atara as of such date.
Atara is providing this stock option information in accordance with NASDAQ Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases who have been underserved by scientific innovation, with an initial focus on allogeneic T-cell therapies for cancer, autoimmune, and infectious disease. Atara's T-cell product candidates harness the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. The Company's initial clinical stage T-cell product candidates include Epstein-Barr virus targeted Cytotoxic T-cells (EBV-CTL), or ATA129, Cytomegalovirus targeted Cytotoxic T-cells (CMV-CTL), or ATA230, and Wilms Tumor 1 targeted Cytotoxic T-cells (WT1-CTL), or ATA520. These product candidates have demonstrated the potential to have therapeutic benefit in a number of clinical indications including hematologic malignancies, solid tumors, and refractory viral infections. The Company is also developing a next generation of T-cell product candidates utilizing a technology to selectively enhance a T-cell's ability to target specific viral proteins implicated in a disease. The Company’s ATA188 product candidate leverages this technology. Initial clinical investigations employing this approach will focus on multiple sclerosis and other virally mediated cancers and infections.
INVESTOR & MEDIA CONTACTS: Investors: John Craighead, Atara Biotherapeutics 650-491-5806 [email protected] Steve Klass, Burns McClellan 212-213-0006 x331 [email protected] Media: Justin Jackson, Burns McClellan 212-213-0006 x327 [email protected]
